Announcement on Signing of Quadripartite Supervision Agreement Following the Change of Sponsor
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Signing of Quadripartite Supervision Agreement Following the Change of Sponsor
Filed with SSE · Stock code 603538 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Ningbo Menovo Pharmaceutical Co., Ltd. on 6ix
Story so far
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Tofacitinib Citrate Sustained-release Tablets by Wholly-owned Subsidiary
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Acceptance by Shanghai Stock Exchange of Application for 2026 Private Placement of A-Shares
- Announcement on Change of Sponsor and Sponsor Representative
Earlier from Ningbo Menovo Pharmaceutical
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Tofacitinib Citrate Sustained-release Tablets by Wholly-owned Subsidiary
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Acceptance by Shanghai Stock Exchange of Application for 2026 Private Placement of A-Shares
- Announcement on Change of Sponsor and Sponsor Representative
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Ningbo Menovo Pharmaceutical: Announcement on the Dilution of Immediate Returns, Measures to Mitigate Such Dilution and the Undertakings by Relevant Parties in Relation to the 2026 Private Placement of A-Shares (Revised Draft)
Follow Ningbo Menovo Pharmaceutical into a list and get an email when it puts out news.
Follow Ningbo Menovo Pharmaceutical